This review examines how diet affects metabolism via the gut-hypothalamus-adipose tissue axis, indicating potential treatment targets in obesity.
Obesity is a chronic neurometabolic disorder characterized by low-grade systemic inflammation, adipose tissue dysfunction, and impaired central regulation of energy balance. This review summarizes mechanistic and translational evidence showing that diet-induced changes in the gut microbiota contribute to altered signaling along the gut-hypothalamus-adipose tissue axis. Obesogenic diets modify microbial metabolic activity by reducing short-chain fatty acid production, altering bile acid composition, and increasing endotoxin-related signaling, which together impair intestinal barrier function and promote metabolic endotoxemia. These signals reach the brain through endocrine (GLP-1, PYY), immune (cytokines, TLR4-dependent pathways), and neural (vagal/neuropod) routes, and are associated with hypothalamic microinflammation, impaired leptin and insulin signaling, and a persistent orexigenic drive. At the same time, adipose tissue undergoes hypertrophy and immunometabolic remodeling, reinforcing systemic inflammation and central dysregulation in a self-sustaining feedback loop. Incretin-based therapies, including GLP-1 and dual GIP/GLP-1 receptor agonists, act in part through modulation of this axis, including microbiota-related mechanisms. However, the frequent regain of weight after treatment discontinuation indicates that central and peripheral circuits are not fully reprogrammed. Viewing obesity as a disorder of disrupted inter-organ signaling highlights microbial metabolic pathways as relevant targets for more durable metabolic improvement.
No takes yet. Share an insight, caveat, or question.
Barros et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: